SCHEMBL6404086

SCHEMBL6404086

COc1ccc(C(=O)O)c(OCc2ccccc2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.60
KDM4E B2RXH2 2/20 0.59
RAB9A P51151 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NPC1 O15118 1/20 0.59
GAA P10253 1/20 0.59
MCL1 Q07820 1/20 0.59
MRGPRX4 Q96LA9 3/20 0.55
MAOB P27338 2/20 0.55
APP P05067 1/20 0.55
POLB P06746 1/20 0.55
MAPT P10636 1/20 0.55
HTT P42858 1/20 0.55
RECQL P46063 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
CTSV O60911 2/20 0.54
CTSL P07711 2/20 0.54
MTNR1A P48039 1/20 0.54
MTNR1B P49286 1/20 0.54
FOLH1 Q04609 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31550547 1.00 HDAC8 (0.60) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL7900610 0.93 RAB9A (0.58) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL7907533 0.92 MAOB (0.62) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL1647498 0.90 FOLH1 (0.63) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL1448026 0.90 MAOB (0.61) KDM4ERAB9ASMN1; SMN2NPC1GAA
SCHEMBL6450099 0.90 MAOB (0.65) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL4756552 0.89 MAOB (0.63) KDM4ESMN1; SMN2MCL1MAOBCTSV
SCHEMBL11283190 0.88 MAOB (0.59) KDM4ERAB9ASMN1; SMN2NPC1GAA
SCHEMBL11557673 0.88 KDM4E (0.60) HDAC8KDM4ERAB9ASMN1; SMN2NPC1
SCHEMBL5228333 0.88 HDAC8 (0.57) HDAC8KDM4ERAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3710462-B1 BRARTEMICIN ANALOGUES VICTORIA LINK LTD (NZ) 2026-05-13 EP disclosed
US-20240309036-A1 Phenol Compound-Linked Pentagalloyl Glucose Derivatives and Uses Thereof GENTRIBIO INC. (KR) 2024-09-19 US disclosed
CN-111184866-B Combination treatment of bacterial infections 香港中文大学 2023-12-19 CN disclosed
WO-2023214629-A1 PHENOL COMPOUND-LINKED PENTAGALLOYL GLUCOSE DERIVATIVE AND USE THEREOF 주식회사 젠트리바이오 2023-11-09 WO disclosed
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-20230139366-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2023-05-04 US disclosed
US-11510980-B2 Brartemicin analogues VICTORIA LINK LTD. (NZ) 2022-11-29 US disclosed
US-20210177965-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2021-06-17 US disclosed
US-20210177965-A1 BRARTEMICIN ANALOGUES VICTORIA LINK LIMITED (NZ) 2021-06-17 US disclosed
EP-3710462-A1 BRARTEMICIN ANALOGUES Victoria Link Limited (NZ) 2020-09-23 EP disclosed
CN-111184866-A Combination therapy for bacterial infections 香港中文大学 2020-05-22 CN disclosed
WO-2015161830-A1 HETEROAROMATIC DERIVATIVES AND PHARMACEUTICAL APPLICATIONS THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-10-29 WO disclosed
US-6949585-B2 Cyclooctanone derivatives and cyclodecanone derivative, and use thereof EISAI CO., LTD. (JP) 2005-09-27 US disclosed
US-20040082805-A1 Cyclooctanone derivatives and cyclodecanone derivative, and use thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-04-29 US disclosed
EP-1375465-A9 CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF Eisai Co., Ltd. (JP) 2004-04-14 EP disclosed
EP-1375479-A1 PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME Eisai Co., Ltd. (JP) 2004-01-02 EP disclosed
US-4146631-A ANTIALLERGENS, RESPIRATORY DISORDERS MAY & BAKER LIMITED (GB) 1979-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230139366-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, RXFP4 HDAC8 2334/4885KDM4E 3694/4885RAB9A 1030/4885
US-20040082805-A1 Cyclooctanone derivatives and cyclodecanone derivative, and use thereof CCR1, CCL2, CCR5 HDAC8 2718/4885KDM4E 2070/4885RAB9A 4319/4885
US-20240309036-A1 Phenol Compound-Linked Pentagalloyl Glucose Derivatives and Uses Thereof UGGT1, GCK, GCG HDAC8 675/4885KDM4E 968/4885RAB9A 2393/4885
US-20210177965-A1 BRARTEMICIN ANALOGUES RXFP1, RXFP2, CMKLR1 HDAC8 2472/4885KDM4E 3994/4885RAB9A 975/4885
US-11510980-B2 Brartemicin analogues RXFP1, RXFP2, CMKLR1 HDAC8 2472/4885KDM4E 3994/4885RAB9A 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.